1. |
Razumilava N, Gores GJ. Cholangiocarcinoma. Lancet, 2014, 383(9935): 2168-2179.
|
2. |
陈孝平, 项帅. 精准医学时代肝门部胆管癌的治疗. 中华消化外科杂志, 2018, 17(1): 3-8.
|
3. |
Shirai Y, Yoshida K, Tsukada K, et al. Identification of the regional lymphatic system of the gallbladder by vital staining. Br J Surg, 1992, 79(7): 659-662.
|
4. |
Kurosaki I, Tsukada K, Hatakeyama K, et al. The mode of lymphatic spread in carcinoma of the bile duct. Am J Surg, 1996, 172(3): 239-243.
|
5. |
Miyazaki M, Ohtsuka M, Miyakawa S, et al. Classification of biliary tract cancers established by the Japanese Society of Hepato-Biliary-Pancreatic Surgery: 3(rd) English edition. J Hepatobiliary Pancreat Sci, 2015, 22(3): 181-196.
|
6. |
Kayahara M, Nagakawa T, Ueno K, et al. Lymphatic flow in carcinoma of the distal bile duct based on a clinicopathologic study. Cancer, 1993, 72(7): 2112-2117.
|
7. |
中华医学会外科学分会胆道外科学组, 解放军全军肝胆外科专业委员会. 肝门部胆管癌诊断和治疗指南(2013 版). 中华外科杂志, 2013, 51(10): 865-871.
|
8. |
Takada T, Miyazaki M, Miyakawa S, et al. Purpose, use, and preparation of clinical practice guidelines for the management of biliary tract and ampullary carcinomas. J Hepatobiliary Pancreat Surg, 2008, 15(1): 2-6.
|
9. |
Igami T, Nishio H, Ebata T, et al. Surgical treatment of hilar cholangiocarcinoma in the “new era”: the Nagoya University experience. J Hepatobiliary Pancreat Sci, 2010, 17(4): 449-454.
|
10. |
Bagante F, Tran T, Spolverato G, et al. Perihilar cholangiocarcinoma: number of nodes examined and optimal lymph node prognostic scheme. J Am Coll Surg, 2016, 222(5): 750-759.
|
11. |
Mantel HT, Wiggers JK, Verheij J, et al. Lymph node micrometastases are associated with worse survival in patients with otherwise node-negative hilar cholangiocarcinoma. Ann Surg Oncol, 2015, 22(Suppl 3): S1107-S1115.
|
12. |
Amin MB, Edge SB, Greene FL, et al. AJCC Cancer Staging Manual. 8th ed. NewYork: Springer, 2017.
|
13. |
Edge SB, Byrd DR, Compton CC, et al. AJCC Cancer Staging Manual. 7th ed. New York: Springer, 2010.
|
14. |
Mao K, Liu J, Sun J, et al. Patterns and prognostic value of lymph node dissection for resected perihilar cholangiocarcinoma. J Gastroenterol Hepatol, 2016, 31(2): 417-426.
|
15. |
Aoba T, Ebata T, Yokoyama Y, et al. Assessment of nodal status for perihilar cholangiocarcinoma: location, number, or ratio of involved nodes. Ann Surg, 2013, 257(4): 718-725.
|
16. |
Rocha FG, Matsuo K, Blumgart LH, et al. Hilar cholangiocarcinoma: the Memorial Sloan-Kettering Cancer Center experience. J Hepatobiliary Pancreat Sci, 2010, 17(4): 490-496.
|
17. |
Ito K, Ito H, Allen PJ, et al. Adequate lymph node assessment for extrahepatic bile duct adenocarcinoma. Ann Surg, 2010, 251(4): 675-681.
|
18. |
Kambakamba P, Linecker M, Slankamenac K, et al. Lymph node dissection in resectable perihilar cholangiocarcinoma: a systematic review. Am J Surg, 2015, 210(4): 694-701.
|
19. |
Nagino M, Ebata T, Yokoyama Y, et al. Evolution of surgical treatment for perihilar cholangiocarcinoma: a single-center 34-year review of 574 consecutive resections. Ann Surg, 2013, 258(1): 129-140.
|
20. |
Hakeem AR1, Marangoni G, Chapman SJ, et al. Does the extent of lymphadenectomy, number of lymph nodes, positive lymph node ratio and neutrophil-lymphocyte ratio impact surgical outcome of perihilar cholangiocarcinoma? Eur J Gastroenterol Hepatol, 2014, 26(9): 1047-1054.
|
21. |
Kitagawa Y, Nagino M, Kamiya J, et al. Lymph node metastasis from hilar cholangiocarcinoma: audit of 110 patients who underwent regional and paraaortic node dissection. Ann Surg, 2001, 233(3): 385-392.
|